{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:44:09Z","timestamp":1791020649450,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CD40L is a type II membrane glycoprotein of the TNF family that is found on activated T cells, B cells, and platelets. We previously reported that the soluble form of this inflammatory mediator (sCD40L) is elevated in the plasma and cerebrospinal fluid of HIV-1\u2013infected, cognitively impaired individuals. In this study, we demonstrate that the mood-stabilizing drug valproic acid (VPA) reduces sCD40L levels in plasma samples of HIV-1\u2013infected patients (n = 23) and in washed human platelets, which are the main source of circulating sCD40L. VPA also inhibited HIV-1 transactivator of transcription-induced release of sCD40L and platelet factor 4 in C57BL\/6 mice. The mechanism by which VPA was able to do so was investigated, and we demonstrate that VPA, a known glycogen synthase kinase 3\u03b2 inhibitor, blocks platelet activating factor-induced activation of glycogen synthase kinase 3\u03b2 in platelets in a manner that alters sCD40L release from platelets. These data reveal that VPA has antiplatelet activity, and they convey important implications for the potential of VPA as an adjunct therapy not only for cognitively impaired patients with HIV-1 infection, but also numerous inflammatory diseases for which such antiplatelet therapies are currently lacking.<\/jats:p>","DOI":"10.4049\/jimmunol.1001911","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T05:24:38Z","timestamp":1291094678000},"page":"584-591","source":"Crossref","is-referenced-by-count":36,"title":["Antiplatelet Activity of Valproic Acid Contributes to Decreased Soluble CD40 Ligand Production in HIV Type 1-Infected Individuals"],"prefix":"10.1093","volume":"186","author":[{"given":"Donna C","family":"Davidson","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Hirschman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry L","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig N","family":"Morrell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schifitto","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P","family":"Phipps","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay B","family":"Maggirwar","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY 14642"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"2025032410574697700_r1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"2025032410574697700_r2","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1074\/jbc.270.13.7025","article-title":"Recombinant soluble trimeric CD40 ligand is biologically active","volume":"270","author":"Mazzei","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2025032410574697700_r3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/eji.1830250639","article-title":"A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation","volume":"25","author":"Graf","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"2025032410574697700_r4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease","volume":"106","author":"Andr\u00e9","year":"2002","journal-title":"Circulation"},{"key":"2025032410574697700_r5","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1172\/JCI27196","article-title":"Platelets in inflammation and atherogenesis","volume":"115","author":"Gawaz","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2025032410574697700_r6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/mp.50.4.175","article-title":"Role of platelet adhesion in homeostasis and immunopathology","volume":"50","author":"M\u00e4nnel","year":"1997","journal-title":"MP, Mol. Pathol."},{"key":"2025032410574697700_r7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.vph.2008.06.004","article-title":"Endothelium-platelet interactions in inflammatory lung disease","volume":"49","author":"Tabuchi","year":"2008","journal-title":"Vascul. Pharmacol."},{"key":"2025032410574697700_r8","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/01.CIR.0000160349.42665.0C","article-title":"CD40\/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia\/reperfusion","volume":"111","author":"Ishikawa","year":"2005","journal-title":"Circulation"},{"key":"2025032410574697700_r9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0002-9440(10)61744-0","article-title":"Role of CD40-CVD40L in mouse severe malaria","volume":"159","author":"Piguet","year":"2001","journal-title":"Am. J. Pathol."},{"key":"2025032410574697700_r10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1096\/fsb2fasebj.12.1.79","article-title":"Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection","volume":"12","author":"Holme","year":"1998","journal-title":"FASEB J."},{"key":"2025032410574697700_r11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1086\/338572","article-title":"Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1","volume":"185","author":"Wolf","year":"2002","journal-title":"J. Infect. Dis."},{"key":"2025032410574697700_r12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00018-009-0209-x","article-title":"Platelets and viruses: an ambivalent relationship","volume":"67","author":"Flaujac","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"2025032410574697700_r13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archneur.64.9.1264","article-title":"Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus-associated dementia","volume":"64","author":"Wachtman","year":"2007","journal-title":"Arch. Neurol."},{"key":"2025032410574697700_r14","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.4049\/jimmunol.178.5.3226","article-title":"Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia","volume":"178","author":"Sui","year":"2007","journal-title":"J. Immunol."},{"key":"2025032410574697700_r15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1212\/01.wnl.0000204294.28189.03","article-title":"Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report","volume":"66","author":"Schifitto","year":"2006","journal-title":"Neurology"},{"key":"2025032410574697700_r16","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1523\/JNEUROSCI.23-27-09162.2003","article-title":"Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis","volume":"23","author":"Dou","year":"2003","journal-title":"J. Neurosci."},{"key":"2025032410574697700_r17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1046\/j.1471-4159.2000.0721327.x","article-title":"The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3","volume":"72","author":"Chen","year":"1999","journal-title":"J. Neurochem."},{"key":"2025032410574697700_r18","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood-2007-09-111518","article-title":"GSK3\u03b2 is a negative regulator of platelet function and thrombosis","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"2025032410574697700_r19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0014-5793(03)01015-9","article-title":"Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function?","volume":"553","author":"Barry","year":"2003","journal-title":"FEBS Lett."},{"key":"2025032410574697700_r20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1046\/j.1471-4159.1999.0730578.x","article-title":"HIV-1 Tat-mediated activation of glycogen synthase kinase-3\u03b2 contributes to Tat-mediated neurotoxicity","volume":"73","author":"Maggirwar","year":"1999","journal-title":"J. Neurochem."},{"key":"2025032410574697700_r21","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1128\/jvi.68.7.4628-4635.1994","article-title":"Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin","volume":"68","author":"Gelbard","year":"1994","journal-title":"J. Virol."},{"key":"2025032410574697700_r22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/mcne.2002.1117","article-title":"Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons","volume":"20","author":"Hall","year":"2002","journal-title":"Mol. Cell. Neurosci."},{"key":"2025032410574697700_r23","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1242\/jcs.00693","article-title":"Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes","volume":"116","author":"Koivisto","year":"2003","journal-title":"J. Cell Sci."},{"key":"2025032410574697700_r24","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/MCB.23.13.4649-4662.2003","article-title":"Glycogen synthase kinase 3\u03b2-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor \u03baB signaling","volume":"23","author":"Sanchez","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"2025032410574697700_r25","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/AAC.48.11.4328-4331.2004","article-title":"Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults","volume":"48","author":"DiCenzo","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"2025032410574697700_r26","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2008-05-158535","article-title":"15-Deoxy-\u039412,14-PGJ2 enhances platelet production from megakaryocytes","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"2025032410574697700_r27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/ATVBAHA.109.197343","article-title":"Platelets and megakaryocytes contain functional nuclear factor-\u03baB","volume":"30","author":"Spinelli","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2025032410574697700_r28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","article-title":"Valproate-induced thrombocytopenia: a prospective monotherapy study","volume":"49","author":"Nasreddine","year":"2008","journal-title":"Epilepsia"},{"key":"2025032410574697700_r29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.jcp.0000088911.24613.0d","article-title":"Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder","volume":"23","author":"De Berardis","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"2025032410574697700_r30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MBC.0b013e3282f3f9ec","article-title":"High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study","volume":"19","author":"Koenig","year":"2008","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"2025032410574697700_r31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1528-1167.2006.00587.x","article-title":"Valproate-associated coagulopathies are frequent and variable in children","volume":"47","author":"Gerstner","year":"2006","journal-title":"Epilepsia"},{"key":"2025032410574697700_r32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/088307380201700110","article-title":"Coagulation abnormalities and acquired von Willebrand\u2019s disease type 1 in children receiving valproic acid","volume":"17","author":"Serdaroglu","year":"2002","journal-title":"J. Child Neurol."},{"key":"2025032410574697700_r33","doi-asserted-by":"crossref","first-page":"17660","DOI":"10.1074\/jbc.273.28.17660","article-title":"Platelet-activating factor receptor activation: an initiator step in HIV-1 neuropathogenesis","volume":"273","author":"Perry","year":"1998","journal-title":"J. Biol. Chem."},{"key":"2025032410574697700_r34","doi-asserted-by":"crossref","first-page":"39474","DOI":"10.1074\/jbc.M504672200","article-title":"Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow","volume":"280","author":"McCarty","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2025032410574697700_r35","volume-title":"Platelets.","author":"Michelson","year":"2007"},{"key":"2025032410574697700_r36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/292650a0","article-title":"Inhibition of actin polymerization in blood platelets by cytochalasins","volume":"292","author":"Fox","year":"1981","journal-title":"Nature"},{"key":"2025032410574697700_r37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.molmed.2008.09.006","article-title":"CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease","volume":"14","author":"Rizvi","year":"2008","journal-title":"Trends Mol. Med."},{"key":"2025032410574697700_r38","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.1523\/JNEUROSCI.5796-09.2010","article-title":"Dyad of CD40\/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis","volume":"30","author":"Ramirez","year":"2010","journal-title":"J. Neurosci."},{"key":"2025032410574697700_r39","first-page":"635","article-title":"Targeting CD40L: a promising therapeutic approach","volume":"11","author":"Daoussis","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"2025032410574697700_r40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1592\/phco.21.17.1325.34418","article-title":"Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital","volume":"21","author":"Conley","year":"2001","journal-title":"Pharmacotherapy"},{"key":"2025032410574697700_r41","first-page":"15","article-title":"Valproic acid and thrombocytopenia: cross-sectional study","volume":"7","author":"Ko","year":"2001","journal-title":"Hong Kong Med. J."},{"key":"2025032410574697700_r42","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0301-472X(01)00733-0","article-title":"Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets","volume":"29","author":"Schmitt","year":"2001","journal-title":"Exp. Hematol."},{"key":"2025032410574697700_r43","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2005-07-3040","article-title":"Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets","volume":"107","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"2025032410574697700_r44","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.bbrc.2006.05.087","article-title":"Recruitment of active glycogen synthase kinase-3 into neuronal lipid rafts","volume":"345","author":"Sui","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025032410574697700_r45","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/00001756-200312190-00025","article-title":"Glycogen synthase kinase-3\u03b2 is highly activated in nuclei and mitochondria","volume":"14","author":"Bijur","year":"2003","journal-title":"Neuroreport"},{"key":"2025032410574697700_r46","first-page":"167","article-title":"Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase","volume":"114","author":"Otterdal","year":"2004","journal-title":"Thromb. Res."},{"key":"2025032410574697700_r47","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2003.12.055","article-title":"Release of soluble CD40L from platelets is regulated by glycoprotein IIb\/IIIa and actin polymerization","volume":"43","author":"Furman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"2025032410574697700_r48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1160\/TH08-12-0781","article-title":"Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3\u03b2 in platelets","volume":"102","author":"Hayashi","year":"2009","journal-title":"Thromb. Haemost."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/1\/584\/62470399\/1001911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/1\/584\/62470399\/1001911.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:04:04Z","timestamp":1743149044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/186\/1\/584\/8002946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1001911","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,1]]},"published":{"date-parts":[[2011,1,1]]}}}